Retatrutide + MOTS-c
Why this combination
This pairing combines a powerful appetite-and-expenditure agent with a metabolic-conditioning peptide. Retatrutide, the triple-G agonist (GIP/GLP-1/glucagon), drives the weight loss — appetite suppression plus glucagon-mediated energy expenditure. MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene that activates AMPK and is reported to improve insulin sensitivity, glucose handling, and metabolic flexibility, acting in skeletal muscle as a so-called 'exercise mimetic.'
The conceptual case is that retatrutide handles the energy-balance side while MOTS-c supports the quality of the metabolic substrate underneath it — mitochondrial function and insulin sensitivity — potentially helping preserve metabolic rate and muscle responsiveness during a large caloric deficit. Their schedules differ: retatrutide is a once-weekly long-acting peptide, while MOTS-c is short-acting and dosed several times per week.
This is an experimental, community-driven combination. Retatrutide is investigational, and MOTS-c has only just entered human trials (an early study in prediabetes/overweight adults); essentially all MOTS-c dosing is extrapolated from preclinical work and community practice. It is presented at community confidence with that caveat front and center.
Per-compound dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Retatrutide | 2 → 12 mg | Once weekly | Standard Phase 2 titration: 2 mg start, stepping toward 4, 8, or 12 mg as tolerated. |
| MOTS-c | 5–10 mg | 2–3× weekly | Community anchor: 5 mg 2–3× weekly to start, up to 10 mg 2–3× weekly; typically run in 4–8 week blocks. |
Reconstitution math
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Separate vials
Retatrutide — reconstitute a 30 mg vial with 2 mL bacteriostatic water → 15,000 mcg/mL. An 8 mg (8,000 mcg) dose is 0.533 mL (53.3 units); 12 mg is 0.8 mL (80 units).
MOTS-c — reconstitute a 10 mg vial with 2 mL → 5,000 mcg/mL; a 5 mg (5,000 mcg) dose is a full 1.0 mL (100 units). To shrink that draw, mix 10 mg + 1 mL → 10,000 mcg/mL, making 5 mg = 0.5 mL (50 units).
Keep them in separate vials — the once-weekly versus 2–3×-weekly schedules make a shared vial impractical.
Pre-blended (single vial)
Pre-blending does not make sense here because the dosing frequencies differ: retatrutide is injected once weekly while MOTS-c is injected two to three times weekly, so a shared vial would force one of them off its intended schedule.
Run them as separate vials and simply co-inject on the day they overlap. If minimizing injections matters, time the weekly retatrutide dose to coincide with one of the MOTS-c days.
Verify any blend with the reconstitution calculator before dosing — concentrations change for every compound when you alter the water volume.
Cycle length & alternatives
- Cycle length
- Retatrutide is run as a long-term titrated regimen; MOTS-c is typically cycled in 4–8 week blocks. A common approach overlays a MOTS-c block onto an ongoing retatrutide phase rather than matching their durations.
- Compared to alternatives
- Unlike the amylin-based weight-loss stacks (CagriSema, cagrilintide + retatrutide), this pairing does not add a second appetite mechanism — MOTS-c contributes mitochondrial/insulin-sensitivity support rather than satiety. That makes it conceptually closer to pairing a weight-loss agent with a metabolic-conditioning adjunct than to a pure 'stack two anorectics' approach. Evidence for the combination is absent; both components, especially MOTS-c, rest largely on preclinical and early data.
Sources & references
Frequently asked questions
What does MOTS-c contribute to a weight-loss stack?
MOTS-c is a mitochondrial-derived peptide that activates AMPK and is studied for improving insulin sensitivity and metabolic flexibility — an 'exercise-mimetic' role. The idea is to support mitochondrial function and substrate handling alongside retatrutide's appetite and energy-expenditure effects, rather than to add more appetite suppression.
How established is MOTS-c in humans?
Barely. MOTS-c has strong preclinical data but only recently entered human trials (e.g., an early study in prediabetes/overweight adults), so its dosing here is extrapolated from animal work and community use.
Can I inject them at the same time?
They are kept in separate vials because retatrutide is weekly and MOTS-c is 2–3× weekly, but on overlapping days they can be co-injected. Aligning the weekly retatrutide dose with a MOTS-c day reduces total injections.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Related stacks
Cagrilintide + Retatrutide
This is the most aggressive weight-loss combination on paper: it stacks the long-acting amylin analog cagrilintide on top of retatrutide, the triple-G agonist that activates the GIP, GLP-1, and glucagon receptors at once. Retatrutide alone produced the largest weight reductions reported for any pharmacological agent in its Phase 2 trial — about 24% at 48 weeks, with the curve still falling — and the glucagon component adds an energy-expenditure mechanism on top of the appetite suppression shared with other incretins. Adding amylin-mediated satiety layers a fourth, mechanistically distinct hunger signal onto that base.